What imaging modality is used to confirm pheochromocytoma?

Prepare for the Adult-Gerontology Acute Care Nurse Practitioner Test. Study with interactive quizzes and detailed explanations. Boost your exam readiness with our diverse question formats and in-depth content coverage.

Multiple Choice

What imaging modality is used to confirm pheochromocytoma?

The imaging step after biochemical confirmation is to localize the pheochromocytoma so surgery can be planned. CT scanning is most commonly used for this localization because it provides rapid, high-resolution images of the adrenal glands and surrounding structures. It has excellent sensitivity for identifying adrenal tumors, helps determine exact size and location, and can evaluate both adrenal glands in one study, which is critical since pheochromocytomas can be unilateral or bilateral and can occur in an extra-adrenal paraganglion location. MRI is also a strong option because of its superior soft-tissue contrast and lack of ionizing radiation, and it’s particularly useful when CT is contraindicated or when radiation exposure is a concern (eg, in younger patients). However, CT remains the default initial localization tool in many settings due to widespread availability and speed, which is why it’s considered the best answer in this context. Ultrasound has limited sensitivity for pheochromocytoma and is heavily operator-dependent, making it less reliable as a primary confirmatory localization method. PET scans, including specialized tracers, are valuable in certain scenarios—such as indeterminate cases, metastatic disease, or multifocal/paraganglioma evaluations—but they’re not the first-line modality for initial localization after biochemical confirmation.

The imaging step after biochemical confirmation is to localize the pheochromocytoma so surgery can be planned. CT scanning is most commonly used for this localization because it provides rapid, high-resolution images of the adrenal glands and surrounding structures. It has excellent sensitivity for identifying adrenal tumors, helps determine exact size and location, and can evaluate both adrenal glands in one study, which is critical since pheochromocytomas can be unilateral or bilateral and can occur in an extra-adrenal paraganglion location.

MRI is also a strong option because of its superior soft-tissue contrast and lack of ionizing radiation, and it’s particularly useful when CT is contraindicated or when radiation exposure is a concern (eg, in younger patients). However, CT remains the default initial localization tool in many settings due to widespread availability and speed, which is why it’s considered the best answer in this context.

Ultrasound has limited sensitivity for pheochromocytoma and is heavily operator-dependent, making it less reliable as a primary confirmatory localization method. PET scans, including specialized tracers, are valuable in certain scenarios—such as indeterminate cases, metastatic disease, or multifocal/paraganglioma evaluations—but they’re not the first-line modality for initial localization after biochemical confirmation.

More practice questions